2022年12月最新中科院JCR期刊分区表数据（升级版）已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Journal of Medicinal Chemistry J. Med. Chem. LetPub评分 8.3
66人评分
我要评分
声誉 8.9 影响力 7.7 速度 9.4 | |||||||||||||||||||||
| 期刊ISSN | 0022-2623 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| E-ISSN | 1520-4804 | |||||||||||||||||||||
| 2021-2022最新影响因子 （数据来源于搜索引擎） | 注册或登录后，查看影响因子和历年趋势图 | |||||||||||||||||||||
| 2021-2022自引率 | 11.20%注册或登录后，查看自引率趋势图 | |||||||||||||||||||||
| h-index | 240 | |||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||
| 期刊简介 | The Journal of Medicinal Chemistry发表分子结构与生物活性或作用模式之间关系的相关研究。 The Journal of Medicinal Chemistry publishes studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action. Some specific areas that are appropriate include the following: Design, synthesis, and biological evaluation of novel biologically active compounds, diagnostic agents, or labeled ligands employed as pharmacological tools. Molecular modifications of reported series that lead to a significantly improved understanding of their structure-activity relationships (SAR). Routine extensions of existing series that do not utilize novel chemical or biological approaches or do not add significantly to a basic understanding of the SAR of the series will normally not be accepted for publication. Structural biological studies (X-ray, NMR, etc.) of relevant ligands and targets with the aim of investigating molecular recognition processes in the action of biologically active compounds. Molecular biological studies (e.g., site-directed mutagenesis) of macromolecular targets that lead to an improved understanding of molecular recognition. Computational studies that provide fresh insight into the SAR of compound series that are of current general interest or analysis of other available data that subsequently advance medicinal chemistry knowledge. Substantially novel computational chemistry methods with demonstrated value for the identification, optimization, or target interaction analysis of bioactive molecules. Effect of molecular structure on the distribution, pharmacokinetics, and metabolic transformation of biologically active compounds. This may include design, synthesis, and evaluation of novel types of prodrugs. Novel methodology with broad application to medicinal chemistry, but only if the methods have been tested on relevant molecules. | |||||||||||||||||||||
| 期刊官方网站 | https://pubs.acs.org/journal/jmcmar | |||||||||||||||||||||
| 期刊投稿网址 | https://acs.manuscriptcentral.com/acs | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Journal of Medicinal Chemistry的语言要求，还能让Journal of Medicinal Chemistry编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Journal of Medicinal Chemistry编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | Transformative (TJ转换期刊是订阅式/混合期刊，但是正在积极转为完全开放获取期刊。查看ACS说明。) | |||||||||||||||||||||
| 通讯方式 | AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, USA, DC, 20036 | |||||||||||||||||||||
| 出版商 | American Chemical Society | |||||||||||||||||||||
| 涉及的研究方向 | 医学-医药化学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Biweekly | |||||||||||||||||||||
| 出版年份 | 1959 | |||||||||||||||||||||
| 年文章数 | 1032注册或登录后，查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 12.68% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 99.81% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2021-2022年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 注册或登录后，查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0022-2623%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均2.1个月 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 较难 | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Journal of Medicinal Chemistry顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||
| 收稿范围 | 期刊官网数据： 期刊收录研究方向： 药理工具的新型生物活性化合物、诊断剂或标记配体的设计、合成和生物学评估 分子修饰以增进对构效关系（SAR）的认知。（没有创新性的化学或生物学方法或没有对SAR进行深入分析的常规工作通常将不予出版） 有关配体和靶标的结构生物学研究（X射线，NMR等），以探究生物活性化合物作用下的分子识别过程 大分子靶标的分子生物学研究（例如定点诱变）以增进对分子识别的理解 具有最新见解的化合物SAR计算研究，这些化合物当前具有普遍价值，或者可用于分析其他有用数据，从而进一步提高对药物化学的认知 新颖的计算化学方法，对于生物活性分子的鉴定、优化或标靶相互作用分析具有证明价值 分子结构对生物活性化合物的分布、药代动力学和代谢转化的影响。这可能包括新型药物前体的设计、合成和评估 可广泛应用于药物化学的新方法，且该方法已在相关分子上进行测试 | |||||||||||||||||||||
| 收录体裁 | 期刊官网数据： Articles Brief Articles Perspectives Drug Annotations Viewpoint Featured Articles | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 注册或登录后，查看自引率趋势图 |
| 注册或登录后，查看中科院SCI期刊分区趋势图 |
| 注册或登录后，查看年文章数趋势图 |
| 中国学者近期发表的论文 | |
| 1. | Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'- C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection. Author: Wang G1, Dyatkina N1, Prhavc M1, Williams C1, Serebryany V1, Hu Y2, Huang Y2, Wan J2, Wu X2, Deval J1, Fung A1, Jin Z1, Tan H1, Shaw K1, Kang H1, Zhang Q1, Tam Y1, Stoycheva A1, Jekle A1, Smith DB1, Beigelman L1. Journal: J Med Chem. 2019 May 9;62(9):4555-4570. doi: 10.1021/acs.jmedchem.9b00143. Epub 2019 Apr 19. PubMed DOI |
| 2. | Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens. Author: Yang Z1, He S1, Wang J1, Yang Y1, Zhang L1, Li Y2, Shan A1. Journal: J Med Chem. 2019 May 9;62(9):4586-4605. doi: 10.1021/acs.jmedchem.9b00149. Epub 2019 Apr 19. PubMed DOI |
| 3. | Targeting the Thioredoxin System as a Strategy for Cancer Therapy. Author: Bian M1, Fan R1, Zhao S1,2, Liu W1,3. Journal: J Med Chem. 2019 Apr 16. doi: 10.1021/acs.jmedchem.8b01595. [Epub ahead of print] PubMed DOI |
| 4. | Discovery of [1,2,4]Triazolo[4,3- a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. Author: Qin M1, Cao Q1, Zheng S1, Tian Y1, Zhang H2, Xie J2, Xie H3, Liu Y1, Zhao Y1, Gong P1. Journal: J Med Chem. 2019 May 9;62(9):4703-4715. doi: 10.1021/acs.jmedchem.9b00312. Epub 2019 Apr 19. PubMed DOI |
| 5. | Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer. Author: Zhang Y1,2,3, Wu X1,2,3, Xue X1,4, Li C1, Wang J5, Wang R1, Zhang C1,6, Wang C1,2,3, Shi Y1,2,3, Zou L1,2,3, Li Q1,2,3, Huang Z, Hao X7, Loomes K8, Wu D9, Chen HW, Xu J9, Xu Y1,3. Journal: J Med Chem. 2019 May 9;62(9):4716-4730. doi: 10.1021/acs.jmedchem.9b00327. Epub 2019 Apr 22. PubMed DOI |
| 6. | Discovery of 3-(Indol-5-yl)-indazole Derivatives as Novel Myeloid Differentiation Protein 2/Toll-like Receptor 4 Antagonists for Treatment of Acute Lung Injury. Author: Liu Z1, Chen L2, Yu P1,3, Zhang Y1, Fang B1, Wu C1, Luo W1, Chen X1, Li C1, Liang G1,2. Journal: J Med Chem. 2019 Apr 29. doi: 10.1021/acs.jmedchem.9b00316. [Epub ahead of print] PubMed DOI |
| 7. | Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain. Author: Huang L1, Li H1, Li L2, Niu L1, Seupel R3,4, Wu C1, Cheng W1, Chen C1, Ding B1, Brennan PE3,4, Yang S1. Journal: J Med Chem. 2019 May 9;62(9):4526-4542. doi: 10.1021/acs.jmedchem.9b00096. Epub 2019 Apr 30. PubMed DOI |
| 8. | Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase. Author: Crespo RA1, Dang Q2, Zhou NE1, Guthrie LM3, Snavely TC1, Dong W1, Loesch KA1, Suzuki T4, You L4, Wang W4, O'Malley T5, Parish T5, Olsen DB2, Sacchettini JC1. Journal: J Med Chem. 2019 May 9;62(9):4483-4499. doi: 10.1021/acs.jmedchem.9b00020. Epub 2019 Apr 19. PubMed DOI |
| 9. | Fuplatin: An Efficient and Low-Toxic Dual-Prodrug. Author: Zhang R1, Song XQ1, Liu RP1, Ma ZY1, Xu JY1. Journal: J Med Chem. 2019 May 9;62(9):4543-4554. doi: 10.1021/acs.jmedchem.9b00128. Epub 2019 Apr 30. PubMed DOI |
| 10. | Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension. Author: Wang Z1, Jiang X1, Zhang X1,2, Tian G3, Yang R3, Wu J3, Zou X3, Liu Z4, Yang X4, Wu C4, Shi J4, Li J1, Suo J1, Wang Y1, Zhang R1, Xu Z1, Gong X1,5, He Y1, Zhu W1,2, Aisa HA5, Jiang H1,2, Xu Y1,2, Shen J1,2. Journal: J Med Chem. 2019 May 23;62(10):4979-4990. doi: 10.1021/acs.jmedchem.9b00123. Epub 2019 May 8. PubMed DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共23条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
